David Sourdive

All filings by David Sourdive on record concern Cellectis, in the capacity of senior executive. Between 3 March 2025 and 1 June 2026, the trades on record add up to 6 filings.

The open-market record consists of 4 sales worth €473k, with no purchase. Outside the open market, there are 2 share grants. 2026 to date brings no purchases and 4 sales.

Most recently, on 3 June 2026, the filings show an open-market sale worth €18k in Cellectis. The median gap between a trade and its publication by AMF is 7 days. The legal deadline for notifying a trade is three business days (MAR article 19). Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from AMF disclosures alone and does not predict where the share price will go.